Experts from the BIA got together to discuss how the UK’s biotechnology industry can plug the UK’s worrying skills gap.

Are there learnings from the COVID-19 pandemic that could be applied to the development and commercialization of advanced therapies?

Using CRISPR to engineer cell therapies with multiple gene knockouts could be limited by double-strand breaks.

Is there data demonstrating significant cost benefits from continuous biomanufacturing?

As trials change and adapt, so too must clinical packaging.

How do we choose the right bioprocessing technologies for the short and long term?

How can advocacy groups help improve the clinical trials landscape?

Could zinc finger therapy hold the key to treating Alzheimer’s disease?

Why are some COVID-19 vaccines linked to blood clots? Researchers have a theory...

How is AI helping to combat infectious diseases?